Novo Nordisk’s Rybelsus becomes the first oral Semaglutide (GLP-1) drug to enter the non-insulin diabetes drug market. With three different technologies and close to 15 drugs in the market, the competition is fierce. Fortunately, Rybelsus steers past competitors in many key parameters.
27 Sep 2019
First oral Semaglutide hits the market
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
First oral Semaglutide hits the market
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
27 Sep 2019 -
Author:
Surbhit Gupta -
Pages:
4
Novo Nordisk’s Rybelsus becomes the first oral Semaglutide (GLP-1) drug to enter the non-insulin diabetes drug market. With three different technologies and close to 15 drugs in the market, the competition is fierce. Fortunately, Rybelsus steers past competitors in many key parameters.